Conatus Pharmaceuticals to Participate in Upcoming Investor Conferences
- At the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease (
September 26-27in New York), senior management will conduct a series of scheduled meetings with investment professionals.
- At the Roth Capital Partners Battle of the
NASH Thrones Investor Conference( October 17in New York), senior management will conduct a series of scheduled meetings with investment professionals and participate in a panel discussion on fibrotic, inflammatory and metabolic agents.
Conatus is a biotechnology company focused on the development of novel medicines to treat liver disease. In collaboration with
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward looking statements, including statements regarding: caspase inhibitors' potential to interrupt the progression of a variety of diseases. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those risks described in the company’s prior press releases and in the periodic reports it files with the
Source: Conatus Pharmaceuticals Inc.